Literature DB >> 23358720

Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer.

Dina Schütze1, Karin Milde-Langosch, Isabell Witzel, Achim Rody, Thomas Karn, Marcus Schmidt, Matthias Choschzick, Fritz Jänicke, Volkmar Müller.   

Abstract

BACKGROUND: Carbonic anhydrase IX (CAIX) is involved in pH homeostasis, growth and survival of tumor cells. Besides the membranous form of CAIX, a soluble form is detectable in serum (s-CAIX). Overexpression of CAIX in tumors offers the opportunity for therapeutic strategies such as CAIX targeting antibodies. The aim of this study was to examine the relationships of CAIX mRNA expression and s-CAIX levels with clinicopathological parameters and survival of patients with primary breast cancer.
METHODS: Tumor tissue of 169 primary breast cancer patients was analyzed for RNA expression by microarray analysis (Affymetrix HG-U133A). Concentration of s-CAIX was determined by ELISA in blood samples of 140 patients.
RESULTS: In tumor tissue, CAIX mRNA signal intensities (MAS5 values) ranged from 34 to 2,513. Higher CAIX expression was associated with younger age (</≥50 years p = 0.040), negative hormone receptors (estrogen receptor p = 0.004; progesterone receptor p = 0.022) and positive nodal status (p = 0.001) as well as with shorter disease-free survival (p = 0.031). Concentrations of s-CAIX ranged from 56 to 1,500 pg/ml. There was no correlation between s-CAIX and CAIX mRNA levels as well as clinicopathological characteristics or outcome.
CONCLUSION: In contrast to reported immunohistochemical studies, we performed RNA-based tissue analyses of CAIX expression and, for the first time, analyzed CAIX serum levels in primary breast cancer. The correlations between CAIX RNA expression and prognostic factors and patient outcome support a biologic role of CAIX in early breast cancer. A role of s-CAIX in primary breast cancer is not supported by our findings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358720     DOI: 10.1007/s00432-013-1378-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK.

Authors:  Daniel F Hayes; Stephen Ethier; Marc E Lippman
Journal:  Breast Cancer Res Treat       Date:  2006-06-14       Impact factor: 4.872

2.  Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.

Authors:  Guorong Li; Gang Feng; Anne Gentil-Perret; Christian Genin; Jacques Tostain
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450

3.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

Authors:  S Ivanov; S Y Liao; A Ivanova; A Danilkovitch-Miagkova; N Tarasova; G Weirich; M J Merrill; M A Proescholdt; E H Oldfield; J Lee; J Zavada; A Waheed; W Sly; M I Lerman; E J Stanbridge
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Expression of MaTu-MN protein in human tumor cultures and in clinical specimens.

Authors:  J Závada; Z Závadová; S Pastoreková; F Ciampor; J Pastorek; V Zelník
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

5.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

Authors:  S K Chia; C C Wykoff; P H Watson; C Han; R D Leek; J Pastorek; K C Gatter; P Ratcliffe; A L Harris
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.

Authors:  Matthias Choschzick; Egbert Oosterwijk; Volkmar Müller; Linn Woelber; Ronald Simon; Holger Moch; Pierre Tennstedt
Journal:  Virchows Arch       Date:  2011-06-21       Impact factor: 4.064

7.  Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells.

Authors:  Matthew Stoner; Bradley Saville; Mark Wormke; Dana Dean; Robert Burghardt; Stephen Safe
Journal:  Mol Endocrinol       Date:  2002-10

8.  Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.

Authors:  Volkmar Müller; Sabine Riethdorf; Brigitte Rack; Wolfgang Janni; Peter A Fasching; Erich Solomayer; Bahriye Aktas; Sabine Kasimir-Bauer; Julia Zeitz; Klaus Pantel; Tanja Fehm
Journal:  Breast Cancer Res       Date:  2011-07-11       Impact factor: 6.466

9.  Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.

Authors:  S A Hussain; R Ganesan; G Reynolds; L Gross; A Stevens; J Pastorek; P G Murray; B Perunovic; M S Anwar; L Billingham; N D James; D Spooner; C J Poole; D W Rea; D H Palmer
Journal:  Br J Cancer       Date:  2007-01-15       Impact factor: 7.640

Review 10.  Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer.

Authors:  C P S Potter; A L Harris
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  11 in total

1.  Roles of Carbonic Anhydrase IX in Development of Pancreatic Cancer.

Authors:  Yuji Li; Ming Dong; Weiwei Sheng; Longping Huang
Journal:  Pathol Oncol Res       Date:  2015-07-30       Impact factor: 3.201

Review 2.  Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors.

Authors:  Olga Sedlakova; Eliska Svastova; Martina Takacova; Juraj Kopacek; Jaromir Pastorek; Silvia Pastorekova
Journal:  Front Physiol       Date:  2014-01-08       Impact factor: 4.566

3.  Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.

Authors:  Laura S Jiwa; Paul J van Diest; Laurien D Hoefnagel; Jelle Wesseling; Pieter Wesseling; Cathy B Moelans
Journal:  BMC Cancer       Date:  2014-11-22       Impact factor: 4.430

4.  [Significance of detection of serum carbonic anhydrase IX in the diagnosis of lung cancer].

Authors:  Fangyuan Cheng; Xiao'e Wang; Diansheng Zhong; Linlin Sun; Qian Wang; Chang Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-01

5.  Sulfonamide derivative targeting carbonic anhydrase IX as a nuclear imaging probe for colorectal cancer detection in vivo.

Authors:  Siao-Syun Guan; Chun-Chia Cheng; Ai-Sheng Ho; Chia-Chi Wang; Tsai-Yueh Luo; Tse-Zung Liao; Jungshan Chang; Cheng-Tien Wu; Shing-Hwa Liu
Journal:  Oncotarget       Date:  2015-11-03

6.  The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer.

Authors:  Keun-Yong Eom; Min Hye Jang; So Yeon Park; Eun Young Kang; Sung Won Kim; Jee Hyun Kim; Jae-Sung Kim; In Ah Kim
Journal:  Cancer Res Treat       Date:  2015-03-03       Impact factor: 4.679

7.  Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy.

Authors:  Ivana Vidlickova; Franck Dequiedt; Lenka Jelenska; Olga Sedlakova; Michal Pastorek; Stanislav Stuchlik; Jaromir Pastorek; Miriam Zatovicova; Silvia Pastorekova
Journal:  BMC Cancer       Date:  2016-03-19       Impact factor: 4.430

8.  Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.

Authors:  Ursa Brown-Glaberman; Marilyn Marron; Pavani Chalasani; Robert Livingston; Maria Iannone; Jennifer Specht; Alison T Stopeck
Journal:  Dis Markers       Date:  2016-01-28       Impact factor: 3.434

9.  [Value of Detection of CAIX in the Pleural Effusion and Its Sediment in the Diagnosis of Lung Cancer].

Authors:  Lina Peng; Xiao'e Wang; Diansheng Zhong; Qian Wang; Chang Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-11

10.  Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis.

Authors:  Fabian Finkelmeier; Özge Canli; Kai-Henrik Peiffer; Dirk Walter; Andrea Tal; Christine Koch; Ursula Pession; Johannes Vermehren; Jörg Trojan; Stefan Zeuzem; Albrecht Piiper; Florian R Greten; Georgios Grammatikos; Oliver Waidmann
Journal:  PLoS One       Date:  2018-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.